(α-Chlor-aethyl)-(p-tolyl)-sulfon

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (α-Chlor-aethyl)-(p-tolyl)-sulfon
• 英文别名: 1-(1-Chloroethylsulfonyl)-4-methylbenzene
• 化学式: C₉H₁₁ClO₂S
• 分子量: 218.704
• InChiKey: WRCVOIFUMLKYCI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  42.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (α-Chlor-aethyl)-(p-tolyl)-sulfon 在 potassium tert-butylate 作用下， 以 四氢呋喃 为溶剂， 生成 6-phenyl-5-<1-(p-tolylsulfonyl)ethyl>-1,2,4-triazine
  参考文献：
  名称：

  Rykowski, Andrzej; Makosza, Mieczyslaw, Liebigs Annalen der Chemie, 1988, p. 627 - 632

  摘要：

  DOI：
• 作为产物：
  描述：

  1-phenyl-2-tosylpropan-1-one 在 sodium hydroxide 、 potassium chloride 、 双氧水 作用下， 以 丙酮 为溶剂， 反应 5.5h， 生成 (α-Chlor-aethyl)-(p-tolyl)-sulfon
  参考文献：
  名称：

  Chemoselective mono halogenation of β-keto-sulfones using potassium halide and hydrogen peroxide; synthesis of halomethyl sulfones and dihalomethyl sulfones

  摘要：

  The synthesis of alpha-halo beta-keto-sulfones using potassium halide and hydrogen peroxide as a chemoselective mono halogenation reagent and the synthesis of alpha, alpha-symmetrical and asymmetrical dihalo beta-keto-sulfones and alpha-halo, alpha-alkyl and beta-keto-sulfones is described. Base induced cleavage of alpha-halo beta-keto-sulfones, alpha,alpha-dihalo beta-keto-sulfones, and alpha-halo, alpha-alkyl beta-keto-sulfones afforded the corresponding halomethyl sulfones, dihalomethyl sulfones and haloalkyl sulfones. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2006.11.129

文献信息

• Heterocyclic beta-3 adrenergic receptor agonists
  申请人：American Home Products Corporation

  公开号：US20020028832A1

  公开（公告）日：2002-03-07

  This invention provides compounds of Formula I having the structure 1 U, V, W, X, and Y are as defined hereinbefore, or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.

  这项发明提供了具有结构式I的化合物 1 其中U、V、W、X和Y如前文所定义， 或其药学上可接受的盐，用于治疗或抑制与胰岛素抵抗或高血糖相关的代谢紊乱（通常与肥胖或葡萄糖不耐受有关）、动脉粥样硬化、胃肠道疾病、神经炎症、青光眼、眼压增高和频繁排尿；特别适用于治疗或抑制2型糖尿病。
• Favorskii rearrangement of α-chloro β-keto sulfones with amines: a new synthesis of amides and α,β-unsaturated amides from aldehydes and ketons
  作者：Tsuyoshi Satoh、Kazuko Oguro、Jun-ichi Shishikura、Naomi Kanetaka、Reiko Okada、Koji Yamakawa

  DOI：10.1016/s0040-4039(00)91645-9

  日期：1992.3

  The Favorskii rearrangement of α-chloro β-keto sulfones, which are easily synthesized from aldehydes and ketones, with amines gives β-sulfonyl amides in good yield. These β-sulfonyl amides are converted to amides and α,β-unsaturated amides by reduction or elimination of the sulfonyl group.

  很容易由醛和酮与胺合成的α-氯代β-酮砜的Favorskii重排反应可得到高产率的β-磺酰基酰胺。通过还原或消除磺酰基，将这些β-磺酰基酰胺转化为酰胺和α，β-不饱和酰胺。
• Favorskii Rearrangement and Carbon–Carbon Bond-Cleavage of<i>α</i>-Chloro-<i>α</i>-sulfonyl Ketones: A Synthesis of Carboxylic Acids and Their Derivatives from Aldehydes and Ketones
  作者：Tsuyoshi Satoh、Kazuko Oguro、Jun-ichi Shishikura、Naomi Kanetaka、Reiko Okada、Koji Yamakawa

  DOI：10.1246/bcsj.66.2339

  日期：1993.8

  derivatives from aldehydes and ketones via α-chloro-α-sulfonyl ketones is described. Acyclic α-chloro-α-sulfonyl ketones were synthesized from aldehydes and 1-chloroalkyl p-tolyl sulfoxides with carbon–carbon coupling in good overall yields. Cyclic α-chloro-α-sulfonyl ketones were synthesized from cyclic ketones in three steps in high overall yields. The Favorskii rearrangement of both acyclic- and cyclic

  描述了一种通过 α-氯-α-磺酰基酮从醛和酮合成羧酸及其衍生物的方法。无环α-氯-α-磺酰基酮由醛和1-氯烷基对甲苯基亚砜以良好的总产率通过碳-碳偶联合成。环状 α-氯-α-磺酰基酮是由环状酮分三步以高总产率合成的。在胺的存在下，无环和环状 α-氯-α-磺酰基酮与氢化钠的 Favorskii 重排得到骨架重排的 β-磺酰胺，收率良好至极好。酰胺和α,β-不饱和酰胺由β-磺酰胺合成。
• Heterocyclic Beta-3 adrenergic receptor agonists
  申请人：American Home Products Corporation

  公开号：US20020022638A1

  公开（公告）日：2002-02-21

  This invention provides compounds of Formula I having the structure 1 wherein, 2 U, V, and W are as defined hereinbefore, or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.

  这项发明提供了具有结构1的Formula I化合物，其中，U、V和W如前文所定义，或其药用盐，这些化合物在治疗或抑制与胰岛素抵抗或高血糖相关的代谢紊乱（通常与肥胖或葡萄糖不耐症相关）、动脉粥样硬化、胃肠道疾病、神经炎症、青光眼、眼压增高和频繁排尿方面具有用处；特别适用于治疗或抑制2型糖尿病。
• Nucleophilic substitution reactions, molecular aggregation, structure and lipophilicity of 6-chloro-3-chloromethyl-1,2,4-triazolo[4,3-b]pyridazine
  作者：Anna Katrusiak、Andrzej Katrusiak

  DOI：10.3998/ark.5550190.0011.929

  日期：——

  The synthesis of 6-chloro-3-chloromethyl-1,2,4-triazolo[4,3-b]pyridazine and its vicarious nucleophilic substitution products are described and characterized by spectroscopic methods and X-ray diffraction. The lipophilicities of the title compound, its acetate, and the derived 3-methyl tetrazolopyridazine have been measured and correlated with the chlorine substitution. The title compound co-crystallizes

  描述了 6-氯-3-氯甲基-1,2,4-三唑并[4,3-b]哒嗪及其替代亲核取代产物的合成，并通过光谱方法和 X 射线衍射进行了表征。已测量标题化合物、其乙酸盐和衍生的 3-甲基四唑并哒嗪的亲油性并与氯取代相关联。尽管取代基和分子间接触显着不同，但标题化合物与乙酸以与其乙酰氧基甲基类似物的晶体相同的对称性和非常相似的层状排列的结构共结晶。讨论了分子间相互作用的细节。